Certolizumab pegol is an anti-TNF (anti-tumour necrosis factor) drug. It works by blocking the action of TNF protein and which reduces inflammation. It is currently licensed for the treatment of several chronic inflammatory conditions, including Crohn’s Disease, rheumatoid arthritis, psoriatic arthritis and juvenile arthritis. If licensed for chronic plaque psoriasis in adults it will offer an additional treatment to relieve the symptoms of the condition.
Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
Interventions:
Certolizumab (CDP-870; Cimzia; certolizumab pegol)
Indications:
Plaque psoriasis
Therapeutic Areas:
Dermatology
Year:
2017